Case Control Study
Copyright ©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Pharmacol Ther. Aug 6, 2014; 5(3): 183-190
Published online Aug 6, 2014. doi: 10.4292/wjgpt.v5.i3.183
Ischemic heart disease, factor predisposing to Barrett’s adenocarcinoma: A case control study
Panagiotis Tsibouris, Mark T Hendrickse, Panagiota Mavrogianni, Peter ET Isaacs
Panagiotis Tsibouris, Panagiota Mavrogianni, Gastroenterology Department, NIMTS General Hospital, 11521 Athens, Greece
Mark T Hendrickse, Peter ET Isaacs, Gastroenterology Department, Blackpool Victoria Hospital, Lancashire FY3 8NR, United Kingdom
Author contributions: Tsibouris P and Isaacs PET design the research; Tsibouris P, Hendrickse MT and Isaacs PET performed the research; Tsibouris P analyzed the data; Tsibouris P and Mavrogianni P wrote the paper.
Correspondence to: Panagiotis Tsibouris, PhD, Consultant Gastroenterologist, Gastroenterology Department, NIMTS General Hospital, 10-12 Monis Petraki Street, 11521 Athens, Greece. tsibofam@yahoo.com
Telephone: +30-210-7288107 Fax: +30-210-7257823
Received: November 12, 2013
Revised: April 6, 2014
Accepted: May 8, 2014
Published online: August 6, 2014
Core Tip

Core tip: Esophageal adenocarcinoma is a major health problem. We performed a population based retrospective comparison, shown that ischemic heart disease is twice as common among patients with esophageal adenocarcinoma than among those with uncomplicated Barrett esophagus. Although myocardial infarction was more frequently acquired in patients with esophageal adenocarcinoma, grade III or IV class heart failure was not, because patients with Barrett esophagus and severe heart failure usually have a low life expectancy and rarely survive longer than 2 years. Patients with Barrett esophagus and ischemic heart disease receive aspirin or nitrates every day more frequently than patients with esophageal adenocarcinoma.